



## Medicare Advantage and Dual Medicare-Medicaid Plans Preauthorization and Notification List

Effective Date: 01/01/2024

Revision Date: 06/26/2024

### Medicare Advantage and Dual Medicare-Medicaid Plan Medication Preauthorization List

To request preauthorization: If the drug is billed, dispensed, and administered by a physician's office, infusion clinic or outpatient facility, please fax the request to 1-888-790-9999.

If the drug is billed and shipped from a retail pharmacy to a physician's office or facility, please fax the request to CarePlus Health Plans Pharmacy at 1-800-310-9071.

Brand	Generic	Codes
Abecma intravenous suspension	idecabtagene vicleucel	Q2055
Abraxane <sup>*,†</sup>	nab-paclitaxel <sup>*,†</sup>	J9264
Actemra IV <sup>†</sup>	tocilizumab <sup>†</sup>	J3262
Adakveo	crizanlizumab-tmca	J0791
Adcetris	brentuximab vedotin	J9042
Adstiladrin	nadofaragene firadenovec-vncg	J9029
Aduhelm	aducanumab-avwa	J0172
Adzynma	ADAMTS13, recombinant-krhn	C9399, J3490, J3590
Akynzeo IV	fosnetupitant and palonosetron	J1454

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Aldurazyme	laronidase	J1931
Alimta*	pemetrexed*	J9305
Aliqopa	copanlisib	J9057
Aloxi	Palonosetron HCL	J2469
Alyglo*,†	immune globulin intravenous, human-stwk*,†	C9399, J1599
Alymsys†	bevacizumab-maly†	Q5126
Amondys-45	casimersen	J1426
Amtagvi*	lifileucel*	C9399, J3490, J3590, J9999
Amvuttra	vutrisiran	J0225
Anktiva*	nogapendekin alfa inbakicept-pmln*	C9399, J3490, J3590, J9999
Aphexda	motixafortide	J2277
Aralast NP*,†	alpha 1-proteinase inhibitor*,†	J0256
Aranesp† (Non-ESRD)	darbepoetin alfa†	J0881
Arcalyst	rilonacept	J2793
Asceniv†	immune globulin†	J1554
Asparlas	calaspargase pegol-mknl	J9118
Avastin (authorization only required for oncology/chemotherapy use) †	bevacizumab (oncology only) †	C9257, J9035
Aveed	testosterone undecanoate	J3145
Avsola*,†	infliximab-axxq*,†	Q5121
Azedra	iobenguane I 131	A9590

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Bavencio	avelumab	J9023
Beleodaq	belinostat	J9032
Belrapzo*	bendamustine hydrochloride*	J9036
Bendamustine*	bendamustine hydrochloride*	J9036
bendamustine (Apotex)	bendamustine hydrochloride	J9058
bendamustine (Baxter)	bendamustine hydrochloride	J9059
Bendeka	bendamustine hydrochloride	J9034
Benlysta	belimumab	C9399, J0490, J3590
Beovu <sup>†</sup>	brovacizumab-dbl <sup>†</sup>	J0179
Beriner <sup>†</sup>	c1 esterase inhibitor <sup>†</sup>	J0597
Besponsa	inotuzumab ozogamicin	J9229
Bivigam <sup>†</sup>	immune globulin <sup>†</sup>	J1556
Blenrep*	belantamab mafodotin-blmf*	J9037
Blincyto	blinatumomab	J9039
<b>Blood-clotting factors (see list on Pages 21 to 24)</b>		
bortezomib*	bortezomib*	J9041
bortezomib (Dr. Reddy's)	bortezomib	J9046
bortezomib (Fresenius Kabi)	bortezomib	J9048
bortezomib (Hospira)	bortezomib	J9049
bortezomib (Maia)	bortezomib	J9051
Botox	onabotulinumtoxinA	J0585
Brineura	cerliponase alfa	J0567

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

Brand	Generic	Codes
Briumvi <sup>†</sup>	ublituximab-xiiy <sup>†</sup>	J2329
Breyanzi	lisocabtagene maraleucel	Q2054
Byooviz <sup>†</sup>	ranibizumab-nuna intravitreal solution <sup>†</sup>	Q5124
cabazitaxel (Sandoz)	cabazitaxel	J9064
Carvykti	ciltacabtagene autoleucel	Q2056
Casgevy <sup>*</sup>	exagamglogene autotemcel <sup>*</sup>	C9399, J3490
Cerezyme	imiglucerase	J1786
Cimerli	ranibizumab-eqrn	Q5128
Cimzia	certolizumab pegol	J0717
Cinqair	reslizumab	J2786
Cinryze <sup>†</sup>	C1 esterase inhibitor <sup>†</sup>	J0598
Cinvanti	aprepitant	C9145, J0185
Columvi	glofitamab-gxbm	J9286
Cortrophin Gel	adrenocorticotrophic hormone (ACTH)	J0802
Cosela	trilaciclib	J1448
Cosentyx IV <sup>*,†</sup>	secukinumab <sup>*,†</sup>	C9166, J3490, J3590
Crysvita	burosumab-twza	J0584
Cutaquig <sup>†</sup>	immune globulin <sup>†</sup>	J1551
Cuvitru <sup>†</sup>	immune globulin <sup>†</sup>	J1555
Cyklokapron <sup>*</sup>	tranexamic acid <sup>*</sup>	J3490
Cyamza	ramucirumab	J9308

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Darzalex	daratumumab	J9145
Darzalex Faspro <sup>*</sup>	daratumumab and hyaluronidase-fihj <sup>*</sup>	J9144
Danyelza	naxitamab-gqgk	J9348
Daxxify <sup>†</sup>	daxibotulinumtoxinA-lanm <sup>†</sup>	J0589
Defitelio <sup>*</sup>	defibrotide sodium <sup>*</sup>	C9399, J3490
Docivyx <sup>*</sup>	docetaxel <sup>*</sup>	C9399, J3490, J9999
Doxil	doxorubicin HCL liposome injection	Q2050
Duopa	carbidopa / levodopa	J7340
Dupilixent <sup>*</sup>	dupilumab <sup>*</sup>	C9399, J3590
Durysta <sup>*</sup>	bimatoprost implant <sup>*</sup>	J7351
Dysport	abobotulinumtoxin A	J0586
Elahere	mirvetuximab soravtansine-gynx	J9063
Elaprase	idursulfase	J1743
Elelyso	taliglucerase alfa	J3060
Elevidys	delandistrogene moxeparvovec-rokl	J1413
Elfabrio IV	pegunigalsidase alfa-iwxj	J2508
Elitek	rasburicase	J2783
Elrexfio	elranatamab-bcmm	J1323
Elzonris	tagraxofusp-erzs	J9269
Empaveli <sup>*</sup>	pegcetacoplan <sup>*</sup>	C9399, J3490

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Empliciti	elotuzumab	J9176
Enhertu	fam-trastuzumab deruxtecan-nxki	J9358
Enjaymo	sutimlimab-jome	J1302
Enspryng*	satralizumab-mwge*	C9399, J3490, J3590
Entyvio IV <sup>†</sup>	vedolizumab <sup>†</sup>	J3380
Epkinly	epcoritamab-bysp	J9321
Epogen <sup>*,†</sup>	epoetin alfa <sup>*,†</sup>	J0885, Q4081
Erbix	cetuximab	J9055
Erwinaze	asparaginase erwinia chrysanthemi	J9019
Eskata*	hydrogen peroxide*	C9399, J3490
Euflexxa <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7323
Evenity <sup>†</sup>	romosozumab-aqqg <sup>†</sup>	J3111
Evkeeza <sup>†</sup>	evinacumab-dgnb <sup>†</sup>	J1305
Exondys 51	eteplirsen	J1428
Eylea	aflibercept	J0178
Eylea HD	aflibercept	J0177
Fabrazyme	agalsidase beta	J0180
Fasenra	benralizumab	J0517
Faslodex	fulvestrant	J9395
Feraheme <sup>†</sup>	ferumoxytol <sup>†</sup>	Q0138
Firazyr <sup>*,†</sup>	icatibant <sup>*,†</sup>	J1744

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

Brand	Generic	Codes
Flebogamma*	immune globulin*	J1572
Flebogamma DIF*	immune globulin*	J1572
Flolan*	epoprostenol (injection)*	J1325, J3490, S0155
Folotyn*	pralatrexate*	J9307
Fulphila	pegfilgrastim-jmdb	Q5108
fulvestrant (Fresenius Kabi)	fulvestrant	J9394
fulvestrant (Teva)	fulvestrant	J9393
Fusilev*	levoleucovorin calcium*	J0641
Fyarro	sirolimu protein-bound particles for injectable suspension	J9331
Fylnetra <sup>†</sup>	pegfilgrastim-pbbk <sup>†</sup>	Q5130
GamaSTAN*	immune globulin*	J1460, J1560
GamaSTAN S/D*	immune globulin*	J1460, J1560
Gamifant	emapalumab-lzsg	J9210
Gammagard	immune globulin	J1569
Gammagard S/D*	immune globulin*	J1566
Gammaked*	immune globulin*	J1561
Gammaplex <sup>†</sup>	immune globulin <sup>†</sup>	J1557
Gamunex-C*	immune globulin*	J1561
Gazyva	obinutuzumab	J9301
Gel-One <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7326
Gelsyn-3 <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7328

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Genvisc 850 <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7320
Givlaari	givosiran	J0223
Glassia <sup>†</sup>	alpha 1-proteinase inhibitor <sup>†</sup>	J0257
Granix <sup>†</sup>	tbo-filgrastim <sup>†</sup>	J1447
Growth hormones: Genotropin, Humatrope, Norditropin FlexPro, Nutropin AQ NuSpin, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive	somatropin	J2941
H.P. Acthar Gel	corticotropin	J0801
Haegarda	C1 esterase inhibitor (subcutaneous)	J0599
Herceptin IV <sup>†</sup>	trastuzumab <sup>†</sup>	J9355
Herceptin Hylecta <sup>*,†</sup>	trastuzumab and hyaluronidase-oysk <sup>*,†</sup>	J9356
Herzuma <sup>†</sup>	trastuzumab-pkrb <sup>†</sup>	Q5113
Hizentra	immune globulin	J1559
Hyalgan <sup>*,†</sup>	sodium hyaluronate <sup>*,†</sup>	J7321
Hymovis <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7322
Hyqvia <sup>†</sup>	immune globulin <sup>†</sup>	J1575
Ilaris	canakinumab	J0638
Ilumya <sup>†</sup>	tildrakizumab-asnm <sup>†</sup>	J3245
Iluvien	fluocinolone acetonide	J7313
Imdelltra <sup>*</sup>	tarlatamab-dlle <sup>*</sup>	C9399, J3490, J3590, J9999

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C



Brand	Generic	Codes
Imfinzi	durvalumab	J9173
Imjudo	tremelimumab-actl	J9347
Imlygic	talimogene laherparepvec	J9325
iDose TR 75mcg intracameral implant*	travoprost intracameral implant*	C9399, J3490
Inflectra	infliximab-dyyb	Q5103
infliximab	infliximab	J1745
Injectafer <sup>†</sup>	ferric carboxymaltose <sup>†</sup>	J1439
Istodax	romidespin	J9319
Ixempra	ixabepilone	J9207
Izervay	avacincaptad pegol intravitreal solution	J2782
Jelmyto*	mitomycin*	J9281
Jemperli	dostarlimab-gxly	J9272
Jevtana	cabazitaxel	J9043
Kadcyla	ado-trastuzumab emtansine	J9354
Kalbitor <sup>†</sup>	ecallantide <sup>†</sup>	J1290
Kanjinti	trastuzumab-anns	Q5117
Kanuma	sebelipase alfa	J2840
Keytruda	pembrolizumab	J9271
Khapzory	levoleucovorin	J0642
Kimmtrak	tebentafusp-tebn	J9274
Korsuva*	difelikefalin*	J0879

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Krystexxa	pegloticase	J2507
Kymriah	tisagenlecleucel	Q2042
Kyprolis	carfilzomib	J9047
Lamzede	velmanase alfa-tycv	J0217
Ianreotide (Cipla) <sup>†</sup>	Ianreotide <sup>†</sup>	J1932
Lantidra <sup>*</sup>	donislecel-jujn <sup>*</sup>	C9399, J3490, J3590
Lemtrada <sup>†</sup>	alemtuzumab <sup>†</sup>	J0202
Lenmeldy <sup>*</sup>	atidarsagene autotemcel <sup>*</sup>	C9399, J3490
Legembi	lecanemab-irmb	J0174
Leqvio	inclisiran	J1306
Leukine	sargramostim	J2820
Levoleucovorin <sup>*</sup>	levoleucovorin calcium <sup>*</sup>	J0641
Libtayo	cemiplimab-rwlc	J9119
Loqtorzi <sup>*</sup>	toripalimab-tpzi <sup>*</sup>	C9399, J3490, J3590, J9999
Lucentis	ranibizumab	J2778
Lumizyme	alglucosidase alfa	J0221
Lunsumio	mosunetuzumab-axgb	J9350
Lutathera <sup>†</sup>	lutetium Lu 177 dotatate <sup>†</sup>	A9513
Luxturna	voretigene neparvovec-rzyl	J3398
Lyfgenia <sup>*</sup>	lovotibeglogene autotemcel <sup>*</sup>	C9399, J3490
Macrilen <sup>*</sup>	macimorelin <sup>*</sup>	C9399, J8499
Margenza	margetuximab-cmkb	J9353

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Mepsevii	vestronidase alfa-vjbk	J3397
Mircera	methoxy polyethylene glycol – epoetin beta	J0887, J0888
Monjuvi*	tafasitamab-cxix*	J9349
Monoferri <sup>†</sup>	ferric derisomaltose <sup>†</sup>	J1437
Mozobil*	plerixafor*	J2562
Mvasi	bevacizumab-awwb	Q5107
Mylotarg	gemtuzumab ozogamicin	J9203
Myobloc	rimabotulinumtoxinB	J0587
Naglazyme	galsulfase	J1458
Neulasta*	pegfilgrastim*	J2506
Neulasta Onpro*	pegfilgrastim*	J2506
Neupogen <sup>†</sup>	filgrastim <sup>†</sup>	J1442
Nexviazyme	Avalglucosidase alfa-ngpt	J0219
Ngenla*	somatrogon-ghla*	C9399, J3490, J3590
Nivestym	filgrastim-aafi	Q5110
Nplate	romiplostim	J2796
Nucala	mepolizumab	J2182
Nulibry*	fosdenopterin*	C9399, J3490
Nulojix	belatacept	J0485
Nuwiq	simoctocog alfa	J7209
Nyvepria <sup>*,†</sup>	pegfilgrastim-apgf <sup>*,†</sup>	Q5122
Ocrevus	ocrelizumab	J2350

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Octagam	immune globulin	J1568
Ogivri <sup>†</sup>	trastuzumab-dkst <sup>†</sup>	Q5114
Omisirge <sup>*</sup>	omidubicel-only <sup>*</sup>	C9399, J3490, J3590
OmvoH IV <sup>*,†</sup>	mirikizumab-mrkz <sup>*,†</sup>	C9168, J3490, J3590
Oncaspar	pegaspargase	J9266
Onivyde <sup>†</sup>	irinotecan liposome injection <sup>†</sup>	J9205
Onpattro	patisiran	J0222
Ontruzant <sup>†</sup>	trastuzumab-dttb <sup>†</sup>	Q5112
Opdivo	nivolumab	J9299
Opdualag intravenous vial <sup>†</sup>	nivolumab and relatlimab-rmbw injection <sup>†</sup>	J9298
Orencia IV <sup>†</sup>	abatacept <sup>†</sup>	J0129
Oxlumo	lumasiran	J0224
Ozurdex	dexamethasone intravitreal implant	J7312
paclitaxel protein-bound <sup>†</sup>	paclitaxel protein-bound <sup>†</sup>	J9258
Padcev <sup>*</sup>	enfortumab vedotin-ejfv <sup>*</sup>	J9177
Palynziq <sup>*</sup>	pegvaliase-pqpz <sup>*</sup>	C9399, J3490, J3590
Panzyga <sup>†</sup>	immune globulin <sup>†</sup>	J1599, J1576
Parsabiv	etelcalcetide	J0606
Pedmark IV solution	sodium thiosulfate	J0208
pemetrexed	pemetrexed	J9324
pemetrexed (Accord)	pemetrexed	J9296

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
pemetrexed (Bluepoint)	pemetrexed	J9322
pemetrexed (Hospira)	pemetrexed	J9294, J9323
pemetrexed (Sandoz)	pemetrexed	J9297
pemetrexed (Teva)	pemetrexed	J9314
Pemfexy	pemetrexed injection	J9304
Pemrydi RTU	pemetrexed	J9324
Perjeta	pertuzumab	J9306
Phesgo*	pertuzumab, trastuzumab, and hyaluronidase-zzxf*	J9316
plerixafor*	plerixafor*	J2562
Pluvicto	lutetium Lu 177 vipivotide tetraxetan	A9607
Polivy	polatuzumab vedotin-piiq	J9309
Pombiliti	cipaglucosidase alfa-atga	J1203
Portrazza	necitumumab	J9295
Poteligeo	mogamulizumab-kpkc	J9204
pralatrexate IV*	pralatrexate*	J9307
Prevymis*	letermovir*	C9399, J3490, J8499
Prialt	ziconotide	J2278
Privigen	immune globulin	J1459
Procrit*	epoetin alfa*	J0885, Q4081
Prolastin-C*, †	alpha 1-proteinase inhibitor*, †	J0256
Prolia†	denosumab†	J0897

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Provenge	sipuleucel-T	Q2043
Qalsody	tofersen	J1304
Qutenza	capsaicin/skin cleanser	J7336
Radicava	edaravone	J1301
Reblozyl <sup>†</sup>	luspatercept-aamt <sup>†</sup>	J0896
Releuko <sup>†</sup>	filgrastim-ayow injection <sup>†</sup>	Q5125
Remicade	infliximab	J1745
Remodulin <sup>*</sup>	treprostinil (injection) <sup>*</sup>	J3285, J3490
Renflexis <sup>†</sup>	infliximab-abda <sup>†</sup>	Q5104
Retacrit	epoetin alfa-epbx	Q5105, Q5106
Rethymic <sup>*</sup>	allogeneic processed thymus tissue-agdc <sup>*</sup>	C9399, J3490, J3590
Retisert	fluocinolone acetonide	J7311
Revatio <sup>*</sup>	sildenafil citrate (injection) <sup>*</sup>	J3490, J8499
Riabni <sup>†</sup>	rituximab-arrx <sup>†</sup>	Q5123
Rituxan IV <sup>†</sup>	rituximab <sup>†</sup>	J9312
Rituxan Hycela <sup>†</sup>	rituximab and hyaluronidase <sup>†</sup>	J9311
Rolvedon <sup>†</sup>	(eflapegrastim-xnst) <sup>†</sup>	J1449
Romidespin	romidespin	J9318
Ruconest <sup>†</sup>	C1 esterase inhibitor <sup>†</sup>	J0596
Ruxience <sup>*, †</sup>	rituximab-pvvr <sup>*, †</sup>	Q5119
Rybrevant IV	amivantamab-vmjw	J9061

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Rylaze	asparaginase erwinia chrysanthemi (recombinant)-rywn	J9021
Ryplazim	plasminogen, human-tvmh	J2998
Rystiggo <sup>†</sup>	rozanolixizumab-noli <sup>†</sup>	J9333
Rytelo IV <sup>*</sup>	imetelstat <sup>*</sup>	C9399, J3490
Sajazir <sup>*</sup>	icatibant <sup>*</sup>	J1744
Sandostatin LAR	octreotide	J2353
Saphnelo intravenous solution	anifrolumab-fnia	J0491
Sarclisa <sup>*</sup>	isatuximab-irfc <sup>*</sup>	J9227
Scenesse <sup>*</sup>	afamelanotide <sup>*</sup>	J7352
Signifor LAR <sup>†</sup>	pasireotide <sup>†</sup>	J2502
Simponi ARIA	golimumab	J1602
Sinuva	mometasone furoate	J7402
Skyrizi IV	risankizumab-rzaa	J2327
Skysona <sup>*</sup>	elivaldogene autotemcel <sup>*</sup>	C9399, J3490, J3590
Sodium Hyaluronate <sup>*,†</sup>	sodium hyaluronate <sup>*,†</sup>	C9399, J3490
Sodium Thiosulfate (Hope)	sodium thiosulfate	J0209
Sogroya <sup>*</sup>	somapacitan-beco <sup>*</sup>	C9399, J3490, J3590

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Soliris	eculizumab	J1300
Somatuline Depot	lanreotide	J1930
Spevigo	spesolimab-sbzo	J1747
Spinraza	nusinersen	J2326
Spravato*	esketamine*	C9399, J3490, S0013
Stelara (IV only)	Ustekinumab (IV only)	J3358
Stimufend <sup>†</sup>	pegfilgrastim-fpgk <sup>†</sup>	Q5127
Strensiq*	asfotase alfa*	C9399, J3590
Sustol	granisetron	J1627
Susvimo <sup>†</sup>	ranibizumab <sup>†</sup>	J2779
Syfovre	pegcetacoplan	J2781
Synagis	palivizumab	90378
SynoJoynt <sup>†</sup>	1% sodium hyaluronate <sup>†</sup>	J7331
Synribo	omacetaxine mepesuccinate	J9262
Synvisc*, <sup>†</sup>	hylan G-F 20*, <sup>†</sup>	J7325
Takhzyro <sup>†</sup>	lanadelumab-flyo <sup>†</sup>	J0593
Takhzyro subcutaneous <sup>†</sup>	lanadelumab-flyo <sup>†</sup>	J0593

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C



Brand	Generic	Codes
Talvey	talquetamab-tgvs	J3055
Tecartus	brexucabtagene autoeucel	Q2053
Tecentriq	atezolizumab	J9022
Tecvayli	teclistamab-cqyv	J9380
Tegsedi*	inotersen*	C9399, J3490
Tepezza*	teprotumumab-trbw*	J3241
Tezspire	tezepelumab-ekko	J2356
Tezspire subcutaneous pen injector	tezepelumab-ekko	J2356
Thrombate III	antithrombin III (human)	J7197
Tivdak <sup>†</sup>	tisotumab vedotin-tftv <sup>†</sup>	J9273
Tofidence IV <sup>†</sup>	tocilizumab-bavi <sup>†</sup>	Q5133
Trazimera	trastuzumab-qyyp	Q5116
Treanda	bendamustine hydrochloride	J9033
Triluron <sup>†</sup>	hyaluronate sodium <sup>†</sup>	J7332
Triptodur	triptorelin	J3316
Trisenox	arsenic trioxide	J9017
TriVisc <sup>†</sup>	sodium hyaluronate <sup>†</sup>	J7329

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Trodelvy <sup>*</sup>	sacituzumab govitecan-hziy <sup>*</sup>	J9317
Truxima <sup>†</sup>	rituximab-abbs <sup>†</sup>	Q5115
Tyenne IV <sup>*, †</sup>	tocilizumab-aazg <sup>*, †</sup>	C9399, J3490, J3590
Tysabri <sup>†</sup>	natalizumab <sup>†</sup>	J2323
Tyvaso	treprostinil (inhaled)	J7686
Tzield	teplizumab-mzwv	J9381
Udenyca	pegfilgrastim-cbqv	Q5111
Udenyca Autoinjector	pegfilgrastim-cbqv	Q5111
Udenyca Onbody	pegfilgrastim-cbqv	Q5111
Ultomiris	ravulizumab-cwvz	J1303
Unituxin	dinutuximab	J1246
Uplizna <sup>*</sup>	inebilizumab-cdon <sup>*</sup>	J1823
Uptravi <sup>*</sup>	selexipag <sup>*</sup>	C9399, J3490
Vabysmo	faricimab-svoa injection	J2777
Valstar	valrubicin	J9357
VariZIG	varicella zoster immune globulin	90396

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Vectibix	panitumumab	J9303
Vegzelma <sup>†</sup>	bevacizumab-adcd <sup>†</sup>	Q5129
Velcade <sup>*</sup>	bortezomib <sup>*</sup>	J9041
Veletri <sup>*</sup>	epoprostenol <sup>*</sup>	J1325
Ventavis	iloprost (inhaled)	Q4074
Veopoz <sup>*</sup>	pozelimab-bbfg <sup>*</sup>	C9399, J3490, J3590
Viltepso	viltolarsen	J1427
Vimizim	elosulfase alfa	J1322
Visco-3 <sup>*,†</sup>	sodium hyaluronate <sup>*,†</sup>	J7321
Visudyne <sup>†</sup>	verteporfin <sup>†</sup>	J3396
Vivimusta	bendamustine hydrochloride	J9056
Vpriv <sup>†</sup>	velaglucerase alfa <sup>†</sup>	J3385
Vyepti <sup>*</sup>	eptinezumab-jjmr <sup>*</sup>	J3032
Vyjuvek <sup>*</sup>	beremagene geperpavec-svdt <sup>*</sup>	J3401
Vyondys 53	golodirsen	J1429
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	J9334
Vyvgart Intravenous Solution	efgartigimod alfa-fcab	J9332

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Vyxeos	daunorubicin/cytarabine	J9153
Wainua*	eplontersen injection*	C9399, J3490
Xembify	immune globulin	J1558
Xenpozyme	olipudase alfa-rpcp	J0218
Xeomin	Incobotulinumtoxin A	J0588
Xgeva <sup>*,†</sup>	denosumab <sup>*,†</sup>	J0897
Xipere	triamcinolone acetonide	J3299
Xofigo	radium Ra 223 dichloride	A9606
Xolair	omalizumab	J2357
Yervoy	ipilimumab	J9228
Yescarta	axicabtagene ciloleucel	Q2041
Yondelis	trabectedin	J9352
Yutiq	fluocinolone acetonide intravitreal implant	J7314
Zaltrap	ziv-aflibercept	J9400
Zarxio	filgrastim-sndz	Q5101
Zavesca <sup>*,†</sup>	miglustat <sup>*,†</sup>	J8499
Zemaira*	alpha 1-proteinase inhibitor*	J0256

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Zepzelca <sup>*</sup>	lurbinectedin <sup>*</sup>	J9223
Zevalin	ibritumomab tiuxetan	A9543
Ziextenzo <sup>†</sup>	pegfilgrastim-bmez <sup>†</sup>	Q5120
Zilretta <sup>†</sup>	triamcinolone acetonide <sup>†</sup>	J3304
Zirabev	bevacizumab-bvzr	Q5118
Zoladex	goserelin acetate	J9202
Zolgensma <sup>*</sup>	onasemnogene abeparvovec-xioi <sup>*</sup>	J3399
Zulresso <sup>*</sup>	brexanolone <sup>*</sup>	J1632
Zynlonta	loncastuximab tesirine-lpyl	J9359
Zynteglo <sup>*</sup>	betibeglogene autotemcel <sup>*</sup>	C9399, J3490, J3590
Zynyz	retifanlimab-dlwr	J9345
<b>Blood-clotting Factors</b>		
Advate <sup>*</sup>	antihemophilic factor (recombinant) <sup>*</sup>	J7192
Adynovate	antihemophilic factor (recombinant), PEGylated	J7207
Afstyla	antihemophilic factor (recombinant) single chain	J7210
Alphanate	antihemophilic factor/von Willebrand factor complex (human)	J7186

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
AlphaNine SD*	coagulation factor IX (human)*	J7193
Alprolix	coagulation factor IX (recombinant)	J7201
Altuviio	efanesoctocog alfa	J7214
BeneFix*	coagulation factor IX (recombinant)*	J7195
Beqvez*	fidanacogene elaparvovec-dzkt*	C9399, J3490, J3590, J7199
Coagadex	coagulation factor X (human)	J7175
Corifact	factor XIII concentrate (human)	J7180
Eloctate	antihemophilic factor (recombinant), Fc fusion protein	J7205
Esperoct	antihemophilic factor (recombinant), glycopegylated-exei	J7204
Feiba NF	anti-inhibitor coagulant complex	J7198
Hemgenix	etranacogene dezaparvovec-drlb	J1411
Hemlibra <sup>†</sup>	emicizumab-kxwh <sup>†</sup>	J7170
Hemofil M*	antihemophilic factor (human)*	J7190
Humate-P	antihemophilic factor/von Willebrand factor complex (human)	J7187

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>†</sup>Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Idelvion	antihemophilic factor IX (recombinant)	J7202
Ixinity*	coagulation factor IX (recombinant)*	J7213
Jivi*	antihemophilic factor (recombinant), PEGylated-auci*	J7208
Koate-DVI*	antihemophilic factor (human)*	J7190
Kogenate FS*	antihemophilic factor (recombinant)*	J7192
Kovaltry	antihemophilic factor (recombinant)	J7211
Monoclote-P*	antihemophilic factor (human)*	J7190
Mononine*	coagulation factor IX (human)*	J7193
NovoEight	turoctocog alfa	J7182
NovoSeven RT	coagulation factor VIIa (recombinant)	J7189
Nuwiq	simoctocog alfa	J7209
Obizur	antihemophilic factor (recombinant), porcine sequence	J7188
Profilnine*	factor IX complex*	J7194
Rebinyn	coagulation factor IX (recombinant), GlycoPEGylated	J7203

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C

Brand	Generic	Codes
Recombinate*	antihemophilic factor (recombinant)*	J7192
Rixubis	coagulation factor IX (recombinant)	J7200
Roctavian*	valoctocogene roxaparvovec-rvox*	J1412
SevenFact intravenous solution*	coagulation factor VIIa (recombinant)-jncw*	J7212
Tretten	coagulation factor XIII A-subunit (recombinant)	J7181
Vonvendi	von Willebrand factor (recombinant)	J7179
Wilate	von Willebrand factor/coagulation factor VIII complex (human)	J7183
Xyntha	antihemophilic factor (recombinant)	J7185
Xyntha Solofuse	antihemophilic factor (recombinant)	J7185

\*All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

†Step therapy required through a CarePlus preferred drug as part of preauthorization.

To prevent disruption of care, CarePlus does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to the enrollment. CarePlus may review the services furnished during that active course of treatment against permissible coverage criteria when determining payment.

334802ALL1023 H1019\_MedicationPAL2024P\_C